Case Report
This article is a minireview on the evolutionary course of non-small-cell lung cancer treatment over recent years, and discusses a case involving a patient who tested negative for PD-L1 but experienced a sustained complete response to explore strategies for addressing this specific tumour context.
Review
This review aims to offer a comprehensive update about available therapeutic options for patients with NSCLC harbouring BRAF mutations to guide the physician in the choice of treatment strategies.
Review
The authors review the current treatment landscape for patients with advanced non-small-cell lung cancers harbouring a KRAS G12C mutation, including PD-(L) 1-based therapies and direct KRAS inhibitors as well as sequential treatment options.
Review
ALK-, ROS1- and NTRK-rearranged tumours represent a distinct clinical and molecular entity amongst non-small-cell lung cancer and have the highest frequency amongst young, non-smoker patients. This paper discusses ALK, ROS1 and NTRK-rearranged disease and all the available treatments are evaluated.
